We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-12.52%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.5B
AUM Growth
-$1.54B
Cap. Flow
+$155M
Cap. Flow %
1.63%
Top 10 Hldgs %
41.52%
Holding
149
New
17
Increased
43
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$108M
2
CRVS icon
Corvus Pharmaceuticals
CRVS
+$75.4M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$71.1M
4
LLY icon
Eli Lilly
LLY
+$70.2M
5
UNH icon
UnitedHealth
UNH
+$67.9M

Top Sells

Rank Stock Value
1
HNT
HEALTH NET INC
HNT
+$205M
2
VTRS icon
Viatris
VTRS
+$149M
3
AFFX
Affymetrix Inc
AFFX
+$75.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$59.4M
5
BMY icon
Bristol-Myers Squibb
BMY
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.92%
2 Financials 0.22%
3 Technology 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
51
Insmed
INSM
$22.5B
$44M 0.46%
3,469,900
– –
DMTX
52
DELISTED
Dimension Therapeutics, Inc
DMTX
$42.3M 0.44%
5,397,698
– –
CYH icon
53
Community Health Systems
CYH
$388M
$40.2M 0.42%
2,627,394
-1,465,068
-36% -$22.4M
BLUE
54
DELISTED
bluebird bio
BLUE
$40.2M 0.42%
72,993
+294
+0.4% +$181K
ACAD icon
55
Acadia Pharmaceuticals
ACAD
$4.45B
$39.2M 0.41%
+1,401,600
New +$30.6M
DVAX
56
DELISTED
Dynavax Technologies
DVAX
$38M 0.4%
1,974,700
-497,500
-20% -$10.1M
VRAY
57
DELISTED
ViewRay, Inc.
VRAY
$34.4M 0.36%
+7,989,916
New +$34.4M
ARRY
58
DELISTED
Array Biopharma Inc
ARRY
$31.5M 0.33%
10,689,000
– –
IBB icon
59
iShares Biotechnology ETF
IBB
$9.46B
$29.1M 0.31%
+335,100
New +$30M
OTIC
60
DELISTED
Otonomy, Inc.
OTIC
$27.6M 0.29%
1,850,094
– –
XNPT
61
DELISTED
XENOPORT, INC.
XNPT
$27.1M 0.28%
6,000,400
+232,000
+4% +$1.07M
AGN
62
CALL
DELISTED
Allergan plc
AGN
$26.8M 0.28%
+100,000
New +$28.6M
MDVN
63
DELISTED
MEDIVATION, INC.
MDVN
$23M 0.24%
501,000
+338,000
+207% +$12.3M
SYK icon
64
Stryker
SYK
$135B
$22.7M 0.24%
212,000
+26,000
+14% +$2.56M
INFI
65
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$19.6M 0.21%
3,723,528
-692,772
-16% -$4.24M
PTLA
66
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$17.1M 0.18%
838,100
-463,600
-36% -$14.7M
SVA
67
DELISTED
Sinovac Biotech, Ltd
SVA
$17M 0.18%
2,667,500
– –
LUMO
68
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$14.9M 0.16%
90,778
-15,367
-14% -$3.11M
XNCR icon
69
Xencor
XNCR
$1.44B
$14.9M 0.16%
1,107,022
– –
AFMD
70
DELISTED
Affimed
AFMD
$14.7M 0.15%
393,180
-65,082
-14% -$2.45M
LAB icon
71
Standard BioTools
LAB
$325M
$14.1M 0.15%
1,746,100
-703,800
-29% -$5.08M
PVLA
72
Palvella Therapeutics
PVLA
$2B
$13.8M 0.15%
90,745
– –
GWPH
73
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13.8M 0.14%
190,600
-113,500
-37% -$6.23M
CAH icon
74
Cardinal Health
CAH
$54.6B
$13.6M 0.14%
166,000
+20,000
+14% +$1.63M
FWP
75
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$13.6M 0.14%
114,000
-23,229
-17% -$2.6M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q1 2016 Portfolio in Review

As of Q1 2016, OrbiMed held 149 positions worth $9.5B, down 14% from $11B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q1 2016 filing shows 17 new, 43 increased, 27 reduced and 8 closed positions. Its largest new stake was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M. The largest sale was HEALTH NET INC, an estimated $205M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q1 2016 buy was Corvus Pharmaceuticals: 5,258,450 shares worth $76.2M.
  • OrbiMed added most to Vertex Pharmaceuticals in Q1 2016, an estimated $108M increase.
  • OrbiMed's biggest Q1 2016 reduction was Viatris, cutting an estimated $149M.
  • OrbiMed fully exited HEALTH NET INC in Q1 2016, selling an estimated $205M.
  • OrbiMed's ten largest holdings make up 42% of its $9.5B portfolio in Q1 2016.
  • OrbiMed opened 17 new positions and closed 8 in Q1 2016.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $9.5B.

Based on OrbiMed's 13F filing for Q1 2016, filed 16 May 2016.